Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by GTS Securities LLC

GTS Securities LLC trimmed its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 61.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,655 shares of the medical equipment provider's stock after selling 4,303 shares during the quarter. GTS Securities LLC's holdings in Zimmer Biomet were worth $280,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Roman Butler Fullerton & Co. purchased a new stake in Zimmer Biomet during the fourth quarter worth $473,000. KLCM Advisors Inc. acquired a new stake in shares of Zimmer Biomet during the 4th quarter valued at about $7,825,000. Van ECK Associates Corp increased its stake in shares of Zimmer Biomet by 5.9% in the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock valued at $417,814,000 after purchasing an additional 218,688 shares in the last quarter. MFG Wealth Management Inc. acquired a new position in Zimmer Biomet in the 4th quarter worth about $1,506,000. Finally, Gries Financial LLC acquired a new stake in Zimmer Biomet in the fourth quarter valued at approximately $866,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares of the company's stock, valued at approximately $915,379.20. The trade was a 14.13% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.39% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

ZBH has been the topic of a number of research analyst reports. Truist Financial set a $101.00 price target on shares of Zimmer Biomet in a research note on Tuesday, May 6th. Morgan Stanley decreased their price objective on Zimmer Biomet from $115.00 to $95.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. Royal Bank of Canada cut their price objective on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, May 6th. Raymond James dropped their price target on Zimmer Biomet from $119.00 to $104.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Finally, BTIG Research reiterated a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, Zimmer Biomet has a consensus rating of "Hold" and a consensus price target of $111.53.

Zimmer Biomet Stock Up 0.9%

Shares of NYSE ZBH traded up $0.80 during mid-day trading on Tuesday, reaching $91.91. The company had a trading volume of 1,330,944 shares, compared to its average volume of 1,798,470. The firm has a 50 day simple moving average of $99.19 and a two-hundred day simple moving average of $104.50. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $116.71. The stock has a market cap of $18.18 billion, a P/E ratio of 20.65, a PEG ratio of 1.95 and a beta of 0.78.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm had revenue of $1.91 billion for the quarter, compared to the consensus estimate of $1.89 billion. During the same quarter last year, the business posted $1.94 EPS. The firm's quarterly revenue was up 1.1% compared to the same quarter last year. Sell-side analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Thursday, June 26th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.04%. The ex-dividend date is Thursday, June 26th. Zimmer Biomet's dividend payout ratio is currently 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.